Furthermore, consistent with the cell studies, the combination treatment group survived significantly longer than the single treatment groups for both tumor models (increased by 291% from the control group for EGFR and TERT inhibition and 293% for EGFR and GABPB1 inhibition for U251, 200% for EGFR and TERT inhibition, and 191% for EGFR and GABPB1 inhibition for GS2). This evidence concerns the gene EGFR and neoplasm.